CPG
VRTX icon

Cornerstone Planning Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Cornerstone Planning Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.4K Buy
130
+14
+12% +$6.21K 0.01% 353
2026
Q1 		$49.2K Sell
116
-8
-6% -$3.73K 0.01% 408
2025
Q4 		$59.3K Buy
124
+7
+6% +$3.02K 0.01% 308
2025
Q3 		$599 Buy
117
+2
+2% +$836 ﹤0.01% 1436
2025
Q2 		$43.1K Sell
115
-10
-8% -$4.61K 0.01% 266
2025
Q1 		$61.6K Buy
125
+66
+112% +$30.8K 0.01% 201
2024
Q4 		$26.2K Buy
59
+1
+2% +$464 0.01% 271
2024
Q3 		$27.3K Sell
58
-21
-27% -$10.1K 0.01% 259
2024
Q2 		$37.7K Sell
79
-12
-13% -$5.21K 0.01% 232
2024
Q1 		$36.5K Sell
91
-47
-34% -$19.9K 0.01% 210
2023
Q4 		$56.2K Buy
138
+42
+44% +$15.5K 0.02% 170
2023
Q3 		$33.4K Buy
96
+1
+1% +$350 0.01% 236
2023
Q2 		$33.4K Buy
+95
New +$32K 0.01% 321
2022
Q4 		$13.2K Buy
+43
New +$13.1K 0.01% 556

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cornerstone Planning Group's VRTX Position: Q2 2026 in Review

Cornerstone Planning Group increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $6.21K and bringing the position to 130 shares worth $61.4K. The position accounts for 0.01% of the portfolio, ranked #353.

Cornerstone Planning Group first reported a position in VRTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $61.6K in Q1 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cornerstone Planning Group held 130 shares of Vertex Pharmaceuticals worth $61.4K as of Q2 2026.
  • Cornerstone Planning Group bought 14 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.21K.
  • Vertex Pharmaceuticals made up 0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #353 holding.
  • Cornerstone Planning Group first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Cornerstone Planning Group's Vertex Pharmaceuticals position peaked at $61.6K in Q1 2025.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.